Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin

Möbus, V.; Moll, Roland; Gerharz, Claus Dieter; Kieback, D. G.; Merk, Oliver; Runnebaum, I. B.; Linner, S.; Dreher, L.; Grill, H. J.; Kreienberg, R.

doi:10.1002/(sici)1097-0215(19980729)77:3<415::aid-ijc18>3.0.co;2-6

Cited by 17 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunostaining was heterogeneous between the cells of a same cell line. This has been reported in the literature, notably for cytokeratin and vimentin expression (Mobus et al, 1998a). As expected, markers defined as luminal, such as CK19, were prominent in luminal cell lines.…”

Section: Breast Cell Line Subtyping At the Protein Levelsupporting

confidence: 85%

“…Breast tumour-derived and normal breast-derived cell lines A total of 31 BCL were analysed: BT-20, BT-474, BT-483, CAMA-1, HCC38, HCC1500, HCC1937 (Tomlinson et al, 1998), HCC1954, HME-1, carcinosarcoma-derived Hs578T (Hackett et al, 1977), MCF-7, MCF10A, MDA-MB-134, MDA-MB-157, MDA-MB-175, MDA-MB-231, MDA-MB-453, SK-BR-3, SK-BR-7, T47D, UACC-812, ZR-75-1, ZR-75-30 (http://www.atcc.org/), HMEC-derived 184B5 (ATCC, http://www.atcc.org/), BrCa-MZ-01 (Mobus et al, 1998b), SUM-52, SUM-149, SUM-185, SUM-190, SUM-225 (Ethier et al, 1993;Forozan et al, 1999); http://www.cancer.med.umich.edu/breast_cell/production), and a recently established breast tumour cell line called S68, derived from a pleural effusion of an invasive ductal carcinoma (a kind gift from V. Catros, Cell Biology Department, CHU Rennes, France). All cell lines are derived from carcinomas except MCF-10A, which is derived from a fibrocystic disease, and HME-1 and 184B5, which represent normal mammary tissue.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Gene expression profiling of breast cell lines identifies potential new basal markers

et al. 2005

View full text Add to dashboard Cite

International audienceA better molecular characterization of breast cell lines (BCL) may help discover new markers to apply to tumour samples. We performed gene and protein expression pro. ling of 31 BCL using whole-genome DNA microarrays and immunohistochemistry (IHC) on `cell microarrays' (CMA), respectively. Global hierarchical clustering discriminated two groups of BCL: group I corresponded to luminal cell lines, group II to basal and mesenchymal cell lines. Correlations with centroids calculated from a published `intrinsic 500-gene set' assigned 15 cell lines as luminal, eight as basal and four as mesenchymal. A set of 1.233 genes was differentially expressed between basal and luminal samples. Mesenchymal and basal subtypes were rather similar and discriminated by only 227 genes. The expression of 10 proteins (CAV1, CD44, EGFR, MET, ETS1, GATA3, luminal cytokeratin CK19, basal cytokeratin CK5/6, CD10, and ERM protein moesin) encoded by luminal vs basal discriminator genes confirmed the subtype classification and the validity of the identified markers. Our BCL basal/luminal signature correctly re-classified the published series of tumour samples that originally served to identify the molecular subtypes, suggesting that the identified markers should be useful for tumour classification and might represent promising targets for disease management

show abstract

Section: Breast Cell Line Subtyping At the Protein Levelsupporting

confidence: 85%

Section: Methodsmentioning

confidence: 99%

Gene expression profiling of breast cell lines identifies potential new basal markers

et al. 2005

View full text Add to dashboard Cite

show abstract

“…They included: BT-474, MCF-7, MCF-10F, MDA-MB-157, MDA-MB-175, MDA-MB-231, MDA-MB-453, BrCa-MZ-02, 11 and HBL-100. All cell lines are derived from carcinomas except HBL-100 and MCF-10F.…”

Section: Mammary Carcinoma Cell Linesmentioning

confidence: 99%

Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers

Ginestier

Charafe‐Jauffret

Bertucci

et al. 2002

The American Journal of Pathology

135

126

View full text Add to dashboard Cite

Emerging high-throughput screening technologies are rapidly providing opportunities to identify new diagnostic and prognostic markers and new therapeutic targets in human cancer. Currently, cDNA arrays allow the quantitative measurement of thousands of mRNA expression levels simultaneously. Validation of this tool in hospital settings can be done on large series of archival paraffin-embedded tumor samples using the new technique of tissue microarray. On a series of 55 clinically and pathologically homogeneous breast tumors, we compared for 15 molecules with a proven or suspected role in breast cancer, the mRNA expression levels measured by cDNA array analysis with protein expression levels obtained using tumor tissue microarrays. The validity of cDNA array and tissue microarray data were first verified by comparison with quantitative reverse transcriptase-polymerase chain reaction measurements and immunohistochemistry on full tissue sections, respectively. We found a good correlation between cDNA and tissue array analyses in one-third of the 15 molecules, and no correlation in the remaining twothirds. Furthermore, protein but not RNA levels may have prognostic value; this was the case for MUC1 protein, which was studied further using a tissue microarray containing ϳ600 tumor samples. For THBS1 the opposite was observed because only RNA levels had prognostic value. Thus, differences extended to clinical prognostic information obtained by the two methods underlining their complementarity and the need for a global molecular analysis of tumors at both the RNA and protein levels.

show abstract

“…However, its role in breast cancer has not been extensively examined. TGF-b1 is widely present in various normal and cancer tissues and is involved in many cellular functions, such as proliferation, differentiation, and apoptosis [2]. TGF-b1 is an inhibitor for cell growth in normal breast epithelial cells.…”

Section: Introductionmentioning

confidence: 99%

TGF-β1 and BRCA2 Expression are Associated with Clinical Factors in Breast Cancer

Zhu

Chen

et al. 2011

Cell Biochem Biophys

View full text Add to dashboard Cite

The objective of this study was to investigate the possible association between the expression of transforming growth factor beta-1 (TGF-β1) and breast cancer type2 susceptibility protein (BRCA2) with clinical factors in breast cancer. TGF-β1, BRCA2, human epidermal growth factor receptor2 (HER2), estrogen receptor, and progesterone receptor protein levels were measured in 67 samples from breast cancer patients by immunohistochemistry. The expression of these proteins was correlated with various clinical factors including age, pathohistological grade and status of axillary lymph node implication. TGF-β1 and BRCA2 were expressed in breast cancer tissues and expression of HER2 and TGF-β1 was significantly correlated with BRCA2. The authors conclude that elevated expression of BRCA2 correlates with TGF-β1 and HER2 in breast cancer and these three factors act in synergy to promote cancer. Thus, detection of both TGF-β1 and BRCA2 may therefore assist in the prognosis and treatment of breast cancer.

show abstract

Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin

Cited by 17 publications

References 18 publications

Gene expression profiling of breast cell lines identifies potential new basal markers

Gene expression profiling of breast cell lines identifies potential new basal markers

Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers

TGF-β1 and BRCA2 Expression are Associated with Clinical Factors in Breast Cancer

Contact Info

Product

Resources

About